Tag: Cre

In the United States, more than 2.8 million antimicrobial-resistant infections occur annually, leading to over 35,000 deaths [1.9.1, 1.9.2]. When facing bacteria resistant to powerful drugs like meropenem, the question 'What antibiotic is higher than meropenem?' becomes critical for patient survival.

According to the CDC, antibiotic resistance is a major threat to public health, making infections harder to treat. When faced with the question of **what if meropenem doesn't work?**, clinicians must investigate potential causes, from resistance mechanisms to patient-specific factors, to pivot toward effective alternative therapies.

In a 2024 study, the combination of ceftazidime/avibactam plus meropenem showed remarkable synergistic activity against carbapenem-resistant *Klebsiella pneumoniae*. This specific, advanced combination therapy addresses the critical question: **Can ceftazidime and meropenem be given together?**

The rise of antimicrobial resistance is a global health crisis, with some reports showing a high prevalence of resistance to key hospital antibiotics among *Enterobacteriaceae*. Choosing what antibiotic kills Enterobacteriaceae depends heavily on the specific bacterial strain, the type of infection, and the strain's resistance profile.

Facing a significant threat from rising antimicrobial resistance, Enterobacterales infections require a nuanced approach, making the question 'What is the drug of choice for Enterobacterales?' highly dependent on the specific resistance profile and clinical context. With resistance rates to common antibiotics varying by species and geography, treatment protocols have shifted away from one-size-fits-all solutions.

Carbapenems are potent members of the β-lactam family of antibiotics, often reserved as a last resort for treating severe, drug-resistant bacterial infections [1.2.1, 1.5.1]. So, what class of antibiotics are carbapenems and why are they so critical in modern medicine?

According to the CDC, carbapenem-resistant Enterobacteriaceae (CRE) have been labeled as "nightmare bacteria," responsible for a 50% mortality rate in patients with bloodstream infections. This stark reality underscores the critical question: **Why is carbapenem a last resort?**

According to the Centers for Disease Control and Prevention (CDC), carbapenem-resistant Enterobacterales (CRE) caused approximately 13,100 infections in U.S. hospital patients in 2017 alone, with about 1,100 deaths. The critical public health threat lies in the fact that these bacteria are resistant to carbapenem antibiotics, making the question of what is a drug in CRE a complex challenge for infectious disease specialists.